Your browser is no longer supported. Please, upgrade your browser.
Settings
AIMT Aimmune Therapeutics, Inc. daily Stock Chart
AIMT [NASD]
Aimmune Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.35 Insider Own0.60% Shs Outstand50.77M Perf Week0.65%
Market Cap1.97B Forward P/E- EPS next Y-3.00 Insider Trans-69.68% Shs Float41.61M Perf Month8.63%
Income-115.20M PEG- EPS next Q-0.71 Inst Own86.60% Short Float6.14% Perf Quarter49.50%
Sales- P/S- EPS this Y-0.50% Inst Trans0.99% Short Ratio4.45 Perf Half Y79.18%
Book/sh4.17 P/B9.33 EPS next Y-20.00% ROA-43.30% Target Price55.50 Perf Year104.63%
Cash/sh4.18 P/C9.32 EPS next 5Y34.60% ROE-46.20% 52W Range15.97 - 40.65 Perf YTD2.86%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-4.31% Beta-
Dividend %- Quick Ratio10.30 Sales past 5Y- Gross Margin- 52W Low143.58% ATR1.48
Employees122 Current Ratio10.30 Sales Q/Q- Oper. Margin- RSI (14)58.23 Volatility4.35% 3.89%
OptionableYes Debt/Eq0.00 EPS Q/Q-19.80% Profit Margin- Rel Volume0.39 Prev Close38.83
ShortableYes LT Debt/Eq0.00 EarningsFeb 05 BMO Payout- Avg Volume574.50K Price38.90
Recom1.60 SMA202.26% SMA507.93% SMA20054.68% Volume222,015 Change0.18%
Dec-21-17Initiated Robert W. Baird Outperform $64
Nov-20-17Initiated ROTH Capital Buy
Sep-26-16Initiated JMP Securities Mkt Outperform
Mar-01-16Initiated Wedbush Outperform $42
Nov-17-15Reiterated Piper Jaffray Overweight $35 → $38
Aug-31-15Initiated Piper Jaffray Overweight $35
Aug-31-15Initiated Credit Suisse Outperform $44
Aug-31-15Initiated BofA/Merrill Buy $36
Jan-13-18 10:00AM  How Trading Notes Can Increase Your Profits TheStreet.com
Jan-10-18 08:00AM  Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy Business Wire
Jan-08-18 08:00AM  Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy Business Wire
Jan-03-18 08:00AM  Aimmune Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-13-17 11:18AM  Moore Loss Won't Stop Tax Bill; Bitcoin Plays Are Bubbling TheStreet.com +5.21%
Dec-07-17 08:00AM  Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14 Business Wire
Nov-30-17 03:42PM  Aimmune Therapeutics, Inc. Fundamental Analysis : November 30, 2017 Capital Cube +6.32%
Nov-20-17 08:00AM  Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1 Business Wire
07:35AM  Report: Developing Opportunities within UGI, Party City Holdco, Old Dominion Freight Line, Olin, Aimmune Therapeutics, and Waste Management Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-06-17 08:37AM  Aimmune Therapeutics reports 3Q loss Associated Press
08:30AM  Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018 Business Wire
Nov-01-17 08:00AM  Aimmune Therapeutics to Participate in Four Investor Conferences in November Business Wire
Oct-31-17 08:30AM  Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase 2 Clinical Trial Business Wire
Oct-23-17 01:46PM  DBV Technologies Pain is Aimmune Therapeutics Incs (AIMT) Gain SmarterAnalyst +28.37%
01:27PM  Why DBV Technologies SA Plummeted and Aimmune Therapeutics Inc Skyrocketed Today Motley Fool
09:15AM  DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers TheStreet.com
Oct-20-17 06:17PM  DBV Technologies Plunges By Half On Allergy Drug Trial's Failure Investor's Business Daily
Oct-19-17 08:00AM  Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings Business Wire
Oct-18-17 10:54AM  [$$] Aimmune, DBV: Fighting Over More Than Peanuts Barrons.com
Oct-16-17 09:19AM  Aimmune teams with Regeneron, Sanofi on peanut allergy drug Reuters
07:30AM  Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofis Dupilumab for Peanut Allergy Business Wire
07:20AM  Drugmakers Are Planning to Start a Phase 2 Trial to Cure Peanut Allergy Bloomberg
Oct-09-17 08:38AM  Is the Options Market Predicting a Spike in Aimmune Therapeutics (AIMT) Stock? Zacks
Sep-26-17 08:43AM  Aimmune Therapeutics (AIMT) in Focus: Stock Moves 6.3% Higher Zacks
Sep-06-17 08:00AM  Aimmune Therapeutics to Participate in Three Investor Conferences in September Business Wire
Aug-09-17 08:00AM  Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th Business Wire -7.50%
Aug-08-17 10:30PM  Aimmune Therapeutics reports 2Q loss Associated Press
04:01PM  Aimmune Therapeutics Announces Second Quarter 2017 Financial Results Business Wire
08:00AM  Aimmune Therapeutics Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy Business Wire
Jul-10-17 08:20AM  AVEO Pharmaceuticals (AVEO) Worth a Look: Stock Up 14.8% Zacks
Jul-05-17 08:00AM  Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy Business Wire
Jun-30-17 06:04AM  Aimmune Therapeutics (AIMT) Shares March Higher, Can It Continue? Zacks
Jun-21-17 08:20AM  Dynavax Technologies (DVAX) Catches Eye: Stock Gains 6.6% Zacks
Jun-20-17 06:30AM  Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress Business Wire
Jun-15-17 08:00AM  Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017 Business Wire
Jun-12-17 04:01PM  Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy Business Wire
Jun-08-17 08:00AM  Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th Business Wire
07:50AM  Clearwater project targets peanut allergies American City Business Journals
Jun-07-17 08:00AM  Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy Business Wire
May-15-17 03:16PM  Why These Drug Stocks May Surge Investopedia
May-11-17 08:00AM  Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy Business Wire
May-09-17 08:00AM  Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16 Business Wire
May-08-17 04:05PM  Aimmune Therapeutics reports 1Q loss Associated Press
04:01PM  Aimmune Therapeutics Announces First Quarter 2017 Financial Results Business Wire
May-01-17 04:11PM  Biotechs Cruise On 6-Day Upswing Despite Price Target Cuts For This Duo Investor's Business Daily
Apr-13-17 06:00AM  Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer Business Wire
Apr-11-17 08:43AM  Should You Get Rid of Aimmune Therapeutics (AIMT) Now? Zacks
Mar-21-17 01:04PM  AIMMUNE THERAPEUTICS, INC. Financials
Mar-16-17 10:07AM  Edited Transcript of AIMT earnings conference call or presentation 15-Mar-17 12:00pm GMT Thomson Reuters StreetEvents
Mar-15-17 08:00AM  Aimmune Therapeutics Inc Earnings Call scheduled for 8:00 am ET today
07:17AM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:07AM  Q4 2016 Aimmune Therapeutics Inc Earnings Release - Before Market Open
07:06AM  Aimmune Therapeutics reports 4Q loss Associated Press
07:00AM  Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results Business Wire
Mar-08-17 08:00AM  Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017 Business Wire
Mar-06-17 09:45AM  Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Business Wire
Mar-01-17 08:00AM  Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March Business Wire
Feb-27-17 08:00AM  Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Business Wire +7.13%
Feb-16-17 05:00PM  Aimmune Therapeutics Inc Conference Call to Discuss The Announced AR101 Program Updates scheduled for 5:00 pm ET today
04:30PM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:01PM  Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback Business Wire
Feb-03-17 05:21PM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex +5.40%
Jan-09-17 09:03AM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-04-17 08:00AM  Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-14-16 05:03PM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Dec-11-16 07:26AM  Hedge Funds Arent Crazy About Aimmune Therapeutics Inc (AIMT) Anymore at Insider Monkey
Dec-01-16 07:00AM  Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts Business Wire
Nov-30-16 10:05AM  Aimmune Closes Enrolment in Phase III Peanut Allergy Study -6.97%
Nov-28-16 02:14PM  Aimmune Therapeutics, Inc. :AIMT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
08:01AM  Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy Business Wire
08:00AM  Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science Business Wire
Nov-23-16 04:40PM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Other Events
Nov-21-16 08:00AM  Aimmune Therapeutics to Host Investor Symposium Featuring Leading Experts in Peanut Allergy Business Wire
Nov-14-16 04:25PM  Aimmune Therapeutics reports 3Q loss
04:12PM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:01PM  Aimmune Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update Business Wire
Nov-07-16 08:40AM  Aimmune Therapeutics (AIMT) Catches Eye: Stock Jumps 8.9% +8.42%
07:15AM  Blog Coverage Aimmune Therapeutics Receives $145 Million Funding from Nestle Accesswire
Nov-04-16 03:30PM  Nestle Health bites into Peninsula allergy drug developer at bizjournals.com +8.86%
08:00AM  Aimmune Therapeutics Inc Conference Call to Discuss the Nestl
07:20AM  Nestle invests $145 million in U.S. food allergy company Aimmune
07:12AM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
07:00AM  Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics Business Wire
Oct-31-16 08:00AM  Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences Business Wire
Oct-11-16 08:00AM  Aimmune Therapeutics to Participate in Two Upcoming Medical Meetings Business Wire
Sep-26-16 09:23AM  Coverage initiated on Aimmune Therapeutics by JMP Securities
Sep-22-16 10:35AM  Analyst Has 3 Biotech Stocks to Buy With Over 100% Upside Potential at 24/7 Wall St.
Sep-20-16 05:00PM  Aimmune Therapeutics Inc Conference Call to Discuss the AR101 Clinical Program Updates scheduled for 5:00 pm ET today
04:09PM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib
04:05PM  Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S. Business Wire
Sep-13-16 03:22PM  Aimmune Therapeutics, Inc. :AIMT-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016
Aug-22-16 04:30PM  Aimmune Therapeutics Inc Call to Discuss the Publication of the DEVIL study data and potential implications for development of AR101 scheduled for 4:30 pm ET today
Aug-18-16 08:00AM  Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children Business Wire +8.20%
Aug-16-16 01:12PM  Aimmune Therapeutics Inc (AIMT) Is Bringing A 100 Year Old Treatment Into The 21st Century at Insider Monkey
Aug-10-16 04:49PM  Aimmune Therapeutics reports 2Q loss
04:43PM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:35PM  Aimmune Therapeutics Announces Second Quarter 2016 Financial Results Business Wire
Aug-09-16 08:00AM  Aimmune Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference Business Wire
Aug-03-16 09:55AM  4 Biotech Stocks With Up to 300% Upside Potential and Upcoming Catalysts at 24/7 Wall St.
Jul-05-16 08:00AM  Aimmune Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference Business Wire
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ADELMAN DANIEL C MDChief Medical OfficerJan 16Option Exercise11.459,933113,7339,933Jan 16 06:05 PM
ADELMAN DANIEL C MDChief Medical OfficerJan 16Sale40.009,933397,3200Jan 16 06:05 PM
ADELMAN DANIEL C MDChief Medical OfficerJan 12Option Exercise11.4526,784306,67726,784Jan 16 06:05 PM
ADELMAN DANIEL C MDChief Medical OfficerJan 12Sale40.0026,7841,071,3600Jan 16 06:05 PM
Sheehy Douglas T.See RemarksJan 04Option Exercise12.951,64821,3421,648Jan 08 04:07 PM
Sheehy Douglas T.See RemarksJan 04Sale37.331,64861,5200Jan 08 04:07 PM
Rozenman Mary M.See RemarksJan 02Option Exercise3.026,59119,9186,720Jan 04 04:05 PM
Barrowcliffe Susan E.General Manager, EuropeJan 02Option Exercise3.0275,000226,65075,000Jan 04 04:05 PM
Barrowcliffe Susan E.General Manager, EuropeJan 02Sale37.1475,0002,785,1900Jan 04 04:05 PM
Rozenman Mary M.See RemarksJan 02Sale37.116,591244,590129Jan 04 04:05 PM
ADELMAN DANIEL C MDChief Medical OfficerDec 27Option Exercise11.453,28337,5903,283Dec 29 05:26 PM
ADELMAN DANIEL C MDChief Medical OfficerDec 27Sale40.003,283131,3200Dec 29 05:26 PM
Sheehy Douglas T.See RemarksDec 26Option Exercise19.631,87536,8061,875Dec 28 05:43 PM
Rozenman Mary M.See RemarksDec 26Option Exercise3.0275,010226,68075,139Dec 28 05:45 PM
Sheehy Douglas T.See RemarksDec 26Sale39.441,87573,9500Dec 28 05:43 PM
Rozenman Mary M.See RemarksDec 26Sale38.8875,0102,916,086129Dec 28 05:45 PM
Sheehy Douglas T.See RemarksDec 04Option Exercise12.951,90624,6831,906Dec 06 04:05 PM
Sheehy Douglas T.See RemarksDec 04Sale38.661,90673,6860Dec 06 04:05 PM
Sheehy Douglas T.See RemarksNov 30Option Exercise19.633,75073,6133,750Dec 04 04:05 PM
Sheehy Douglas T.See RemarksNov 30Sale37.003,750138,7500Dec 04 04:05 PM
Sheehy Douglas T.See RemarksNov 09Option Exercise12.951,90524,6701,905Nov 13 05:26 PM
Sheehy Douglas T.See RemarksNov 09Sale33.001,90562,8650Nov 13 05:26 PM
Sheehy Douglas T.See RemarksOct 23Option Exercise14.8047,425701,82934,300Oct 25 04:05 PM
ADELMAN DANIEL C MDChief Medical OfficerOct 23Option Exercise11.4510,000114,50010,000Oct 25 04:05 PM
DILLY STEPHEN GEORGESee RemarksOct 23Sale33.55100,0003,354,538315,308Oct 25 04:05 PM
ADELMAN DANIEL C MDChief Medical OfficerOct 23Sale34.0610,000340,6100Oct 25 04:05 PM
Sheehy Douglas T.See RemarksOct 23Sale34.4447,4251,633,5140Oct 25 04:05 PM
DILLY STEPHEN GEORGEPresident and CEOOct 16Sale26.241,15430,279415,308Oct 18 07:59 PM
DILLY STEPHEN GEORGEPresident and CEOOct 06Sale26.314,047106,468416,462Oct 06 06:02 PM
DILLY STEPHEN GEORGEPresident and CEOOct 05Sale26.2414,689385,495420,509Oct 06 06:02 PM
DILLY STEPHEN GEORGEPresident and CEOOct 04Sale26.2380,1102,101,353435,198Oct 06 06:02 PM
Barrowcliffe Susan E.General Manager, EuropeSep 25Option Exercise3.0220,00060,44020,000Sep 27 04:05 PM
ADELMAN DANIEL C MDChief Medical OfficerSep 25Option Exercise11.4510,000114,50010,000Sep 27 04:06 PM
Barrowcliffe Susan E.General Manager, EuropeSep 25Sale25.0020,000500,0000Sep 27 04:05 PM
DILLY STEPHEN GEORGEPresident and CEOSep 25Sale25.01100,0002,500,790515,308Sep 27 04:05 PM
ADELMAN DANIEL C MDChief Medical OfficerSep 25Sale25.0010,000250,0000Sep 27 04:06 PM
Rozenman Mary M.See RemarksSep 07Option Exercise3.0230,00090,66030,129Sep 11 05:17 PM
Rozenman Mary M.See RemarksSep 07Sale22.5030,000675,000129Sep 11 05:17 PM
Barrowcliffe Susan E.General Manager, EuropeSep 06Option Exercise3.0215,16745,83515,167Sep 07 04:05 PM
Barrowcliffe Susan E.General Manager, EuropeSep 06Sale22.0015,167333,7090Sep 07 04:05 PM
Barrowcliffe Susan E.General Manager, EuropeSep 05Option Exercise3.023,2239,7403,223Sep 07 04:05 PM
Barrowcliffe Susan E.General Manager, EuropeSep 05Sale22.003,22370,9060Sep 07 04:05 PM
Barrowcliffe Susan E.General Manager, EuropeJul 27Option Exercise3.025001,511500Jul 31 05:50 PM
Barrowcliffe Susan E.General Manager, EuropeJul 27Sale22.0050011,0000Jul 31 05:50 PM
DILLY STEPHEN GEORGEPresident and CEOJul 26Sale21.4650,0001,073,110615,308Jul 28 04:31 PM
Barrowcliffe Susan E.General Manager, EuropeJul 25Option Exercise3.024,65014,0524,650Jul 25 06:35 PM
Barrowcliffe Susan E.General Manager, EuropeJul 25Sale22.004,650102,3000Jul 25 06:35 PM
Barrowcliffe Susan E.General Manager, EuropeJul 24Option Exercise3.025001,511500Jul 25 06:35 PM
Barrowcliffe Susan E.General Manager, EuropeJul 24Sale22.0050011,0000Jul 25 06:35 PM
Barrowcliffe Susan E.General Manager, EuropeJul 21Option Exercise3.029602,901960Jul 25 06:35 PM
Barrowcliffe Susan E.General Manager, EuropeJul 21Sale22.0096021,1200Jul 25 06:35 PM
Sheehy Douglas T.See RemarksJul 21Sale21.667,460161,5580Jul 21 07:05 PM
Rozenman Mary M.See RemarksJul 17Option Exercise3.02300907429Jul 17 04:31 PM
Rozenman Mary M.See RemarksJul 17Sale21.383006,414129Jul 17 04:31 PM
Rozenman Mary M.See RemarksJul 14Option Exercise3.025,66617,1235,795Jul 17 04:31 PM
Rozenman Mary M.See RemarksJul 14Sale21.395,666121,175129Jul 17 04:31 PM
Rozenman Mary M.See RemarksJul 13Option Exercise3.028,97427,1199,103Jul 17 04:31 PM
Rozenman Mary M.See RemarksJul 13Sale21.478,974192,658129Jul 17 04:31 PM
Rozenman Mary M.See RemarksJul 05Option Exercise3.0215,06045,51115,189Jul 06 05:01 PM
Rozenman Mary M.See RemarksJul 05Sale21.4015,060322,212129Jul 06 05:01 PM
Barrowcliffe Susan E.General Manager, EuropeJul 03Option Exercise3.0215,00045,33015,000Jul 06 04:05 PM
Rozenman Mary M.See RemarksJul 03Option Exercise3.0230,00090,66030,129Jul 06 05:01 PM
Rozenman Mary M.See RemarksJul 03Sale20.5730,000617,178129Jul 06 05:01 PM
Barrowcliffe Susan E.General Manager, EuropeJul 03Sale20.2615,000303,9110Jul 06 04:05 PM
DILLY STEPHEN GEORGEPresident and CEOJun 23Sale20.2149,400998,591665,308Jun 27 04:06 PM
BJERKHOLT ERICChief Financial OfficerMay 12Buy19.845,00099,2105,000May 15 04:49 PM
DILLY STEPHEN GEORGESee RemarksMay 10Sale20.1560012,090714,708May 12 04:07 PM
DeSouza Warren L.Chief Financial OfficerApr 03Option Exercise3.0215,00045,33035,681Apr 05 04:05 PM
DeSouza Warren L.Chief Financial OfficerApr 03Sale21.5815,000323,73620,681Apr 05 04:05 PM
DeSouza Warren L.Chief Financial OfficerMar 21Option Exercise3.0210,00030,22030,681Mar 23 04:05 PM
DeSouza Warren L.Chief Financial OfficerMar 21Sale22.9510,000229,50020,681Mar 23 04:05 PM